Predicting diarrhea risk from liver cancer combination therapy
Part of Cancer, Digestive system clinical trials.
This study looks at whether your body type (based on Traditional Chinese Medicine) can help predict if you'll get diarrhea from a new combination treatment for liver cancer. The treatment uses two types of drugs: one helps your immune system fight cancer, and the other blocks blood vessels that feed the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hepatocellular carcinoma (a type of liver cancer).
- You are planning to start a treatment that combines an immunotherapy drug with a targeted therapy drug.
- You are 18 years or older and can fill out questionnaires on your own.
- You have normal hearing, speaking, reading, and writing skills.
- You do not have any pre-existing intestinal conditions like chronic diarrhea, inflammatory bowel disease, or intestinal spread of the cancer.
- You have not been using laxatives regularly for a long time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with advanced liver cancer who are starting a new type of treatment that combines targeted therapy to block blood vessel growth and immune therapy to help your body fight the cancer. It looks at how gut bacteria might affect treatment response.
This trial tests how a combination of targeted therapy (TKI) and immunotherapy (ICI) affects the gut bacteria in people with advanced liver cancer that cannot be surgically removed. It aims to see if changes in the microbiome can help predict treatment response.
This trial tests how gut bacteria affect liver cancer treatment. It is for people whose liver cancer worsened after certain targeted and immunotherapy drugs.
This study is creating a database of people with liver cancer (including hepatocellular carcinoma and other types). It aims to collect health information and samples over time to better understand the disease and improve future care. If you join, you will be asked to provide blood and leftover tissue from surgery or biopsy, and to follow up with the research team.
This study looks at how the gut microbiome affects treatment response in patients with advanced liver cancer who are receiving immunotherapy. It involves a colonoscopy to collect samples and may help improve future treatments.
This study looks at how well a combination of liver-directed therapy and immunotherapy works for people with liver cancer that cannot be removed by surgery. It aims to find markers in your blood that might predict if the treatment will shrink the tumor enough to allow surgery later.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.